MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM
Published: 9 Jul 2020
Views: 429
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA
Dr Luciano Costa speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He presents the updated results from the MASTER study, which investigated the combination of daratumumab, carlfizomib, lenalidomide and dexamethasone (Dara-KRd) to treat patients with newly-diagnosed multiple myeloma (NDMM), with the use of MRD-guided post autologous transplantation (AHCT) consolidation, and MRD surveillance.
Dr Costa outlines the study design, main findings and conclusions achieved with the use of this approach in this patient population.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Related Videos
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma
Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain
25 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
26 Jun 2020
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
26 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
16 Jun 2020
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
15 Jun 2020
Background of the KEYLYNK-007 trial for advanced solid tumours
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
13 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
